A detailed history of Vanguard Group Inc transactions in Cytokinetics Inc stock. As of the latest transaction made, Vanguard Group Inc holds 9,997,076 shares of CYTK stock, worth $528 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
9,997,076
Previous 11,016,889 9.26%
Holding current value
$528 Million
Previous $920 Million 23.8%
% of portfolio
0.01%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$63.75 - $108.06 $65 Million - $110 Million
-1,019,813 Reduced 9.26%
9,997,076 $701 Million
Q4 2023

Feb 14, 2024

BUY
$26.88 - $83.49 $7.35 Million - $22.8 Million
273,565 Added 2.55%
11,016,889 $920 Million
Q3 2023

Nov 14, 2023

BUY
$29.46 - $36.61 $13.9 Million - $17.3 Million
472,595 Added 4.6%
10,743,324 $316 Million
Q2 2023

Aug 14, 2023

BUY
$32.62 - $40.75 $2.85 Million - $3.56 Million
87,397 Added 0.86%
10,270,729 $335 Million
Q1 2023

May 15, 2023

BUY
$33.36 - $45.71 $3.68 Million - $5.04 Million
110,238 Added 1.09%
10,183,332 $358 Million
Q4 2022

Feb 10, 2023

BUY
$35.77 - $51.11 $2.92 Million - $4.18 Million
81,760 Added 0.82%
10,073,094 $462 Million
Q3 2022

Nov 14, 2022

BUY
$38.54 - $54.52 $39.7 Million - $56.2 Million
1,031,114 Added 11.51%
9,991,334 $484 Million
Q2 2022

Aug 12, 2022

BUY
$33.93 - $48.92 $7.43 Million - $10.7 Million
219,096 Added 2.51%
8,960,220 $352 Million
Q1 2022

May 13, 2022

BUY
$29.74 - $46.0 $52.1 Million - $80.6 Million
1,751,405 Added 25.06%
8,741,124 $322 Million
Q4 2021

Feb 14, 2022

BUY
$34.35 - $46.38 $57.5 Million - $77.7 Million
1,675,188 Added 31.52%
6,989,719 $319 Million
Q3 2021

Nov 12, 2021

BUY
$18.54 - $35.74 $10.9 Million - $21 Million
588,842 Added 12.46%
5,314,531 $190 Million
Q2 2021

Aug 13, 2021

BUY
$19.79 - $26.99 $93.5 Million - $128 Million
4,725,689 New
4,725,689 $93.5 Million

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.97B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.